New Delhi, Sep 4: India is making a fresh push to connect scientific innovation with private investment as the government launches BIO-NIVESH, a platform designed to bring biotechnology startups and investors closer and help promising technologies move from research and development to the market.
Launched by Union Minister for Science and Technology Dr Jitendra Singh, the initiative is aimed at addressing a familiar challenge for biotechnology companies — having a strong scientific idea but struggling to secure the capital, partnerships and industry support required to take it to commercial scale.
BIO-NIVESH is intended to create a more direct channel between innovators and the investment community. Startups will get an opportunity to understand investor expectations and present their technologies, while investors can gain a better understanding of the science, development timelines, regulatory requirements and commercial potential involved in biotech businesses.
The first edition brought together 20 biotechnology and deep-tech startups with around 50 investors. The discussions focused not only on raising funds but also on opportunities for strategic partnerships, manufacturing, market access and scaling innovative technologies.
For biotech entrepreneurs, access to capital can be particularly challenging because developing a new product often takes considerably longer than building a conventional technology startup. Drug discovery, diagnostics, vaccines, agricultural technologies and industrial biotechnology can require extensive research, testing, regulatory approvals and manufacturing capabilities before reaching customers.
This makes private investment especially important at the stage when a company has demonstrated scientific potential but needs substantial funding to move towards commercialisation. BIO-NIVESH is designed to help bridge that gap by bringing investors into closer contact with innovators and their technology-development journeys.
The government is also looking at ways to build larger Indian biotechnology companies capable of competing internationally. During the interaction, Singh proposed exploring a “Big Five in Five Years” approach, aimed at developing a group of strong anchor companies that could help drive the growth of the broader biotech ecosystem.
The push comes as biotechnology becomes increasingly important across healthcare, agriculture, sustainable manufacturing, industrial applications and other emerging sectors. India already has a growing base of biotech startups and research institutions, while government programmes are seeking to strengthen the connection between research, entrepreneurship and industry.
The country’s wider bioeconomy is also expanding rapidly. Industry estimates cited by IBEF project India’s bioeconomy could reach around $300 billion by 2030, supported by government policies, private investment, research and growing demand for biotechnology-based solutions.
For the economy, a successful biotech ecosystem can create value well beyond individual startups. Commercially successful technologies can lead to new manufacturing facilities, specialised laboratories, supply chains, exports and high-skilled employment in areas such as research, engineering, data science, regulatory affairs and product development.
The government has also highlighted the ₹1 lakh crore Research, Development and Innovation Fund, under which the Biotechnology Industry Research Assistance Council has been designated as a second-level fund manager for biotechnology and allied sectors. The funding framework is expected to support technology development, scale-up and innovation-led manufacturing.
What makes BIO-NIVESH significant is its attempt to address the gap between invention and commercial success. A promising technology can remain inside a laboratory for years if it does not find the right investors, manufacturing partner or route to market.
For investors, the platform provides an opportunity to identify technologies with the potential to address large markets. For startups, the benefits can extend beyond funding, as experienced investors and industry partners can provide access to expertise, manufacturing networks, customers and international markets.
The initiative is expected to become a recurring platform, with future editions potentially connecting biotechnology innovators in different cities with investment networks. This could help broaden access to capital and give startups outside established technology hubs a greater opportunity to attract investors.
The real test of BIO-NIVESH will ultimately be measured by what happens after the meetings — whether partnerships are formed, private capital reaches promising companies, technologies move into production and Indian biotech businesses are able to compete in global markets.
For India, the opportunity is considerable. The country has scientific talent, a growing startup base and strong demand for innovation in healthcare, agriculture, sustainability and advanced manufacturing. If investment can be connected more effectively with that pool of scientific talent, BIO-NIVESH could help turn more Indian research into products, companies and technologies with real economic value.